[go: up one dir, main page]

UA116915C2 - Вектор, що кодує антигенний пептид, та спосіб підвищення стійкості до інфекцій, що викликаються campylobacter - Google Patents

Вектор, що кодує антигенний пептид, та спосіб підвищення стійкості до інфекцій, що викликаються campylobacter

Info

Publication number
UA116915C2
UA116915C2 UAA201604997A UAA201604997A UA116915C2 UA 116915 C2 UA116915 C2 UA 116915C2 UA A201604997 A UAA201604997 A UA A201604997A UA A201604997 A UAA201604997 A UA A201604997A UA 116915 C2 UA116915 C2 UA 116915C2
Authority
UA
Ukraine
Prior art keywords
antigenic peptide
vector coding
campylobacter infections
improving influence
campylobacter
Prior art date
Application number
UAA201604997A
Other languages
English (en)
Inventor
Біллі Харджис
Нейл Р. Памфорд
Янг Мін Квон
Шеррілл Лейтон
Original Assignee
Дзе Борд Оф Трастіз Оф Дзе Юніверсіті Оф Арканзас
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Борд Оф Трастіз Оф Дзе Юніверсіті Оф Арканзас filed Critical Дзе Борд Оф Трастіз Оф Дзе Юніверсіті Оф Арканзас
Publication of UA116915C2 publication Critical patent/UA116915C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Винахід стосується вектора, що кодує антигенний пептид (cjaA, cj0982), та фармацевтичної композиції, яка його включає. Винахід також стосується способу посилення імунної відповіді у пацієнта, способу підвищення стійкості до інфекції, що викликається Campylobacter, що включає введення пацієнту даного вектора.
UAA201604997A 2010-06-09 2011-06-09 Вектор, що кодує антигенний пептид, та спосіб підвищення стійкості до інфекцій, що викликаються campylobacter UA116915C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35303910P 2010-06-09 2010-06-09
UAA201300278A UA113496C2 (xx) 2010-06-09 2011-06-09 Вектор і спосіб підвищення стійкості до інфекції, що викликається campylobacter

Publications (1)

Publication Number Publication Date
UA116915C2 true UA116915C2 (uk) 2018-05-25

Family

ID=45098670

Family Applications (2)

Application Number Title Priority Date Filing Date
UAA201300278A UA113496C2 (xx) 2010-06-09 2011-06-09 Вектор і спосіб підвищення стійкості до інфекції, що викликається campylobacter
UAA201604997A UA116915C2 (uk) 2010-06-09 2011-06-09 Вектор, що кодує антигенний пептид, та спосіб підвищення стійкості до інфекцій, що викликаються campylobacter

Family Applications Before (1)

Application Number Title Priority Date Filing Date
UAA201300278A UA113496C2 (xx) 2010-06-09 2011-06-09 Вектор і спосіб підвищення стійкості до інфекції, що викликається campylobacter

Country Status (23)

Country Link
US (2) US8961990B2 (uk)
EP (2) EP2579901B1 (uk)
JP (1) JP5746333B2 (uk)
KR (3) KR102007132B1 (uk)
CN (1) CN102971008B (uk)
AR (1) AR081856A1 (uk)
AU (3) AU2011264772B2 (uk)
BR (1) BR112012031211A2 (uk)
CA (1) CA2800830C (uk)
CL (1) CL2012003458A1 (uk)
CO (1) CO6670521A2 (uk)
DK (1) DK2579901T3 (uk)
EA (1) EA030793B1 (uk)
ES (1) ES2753142T3 (uk)
HU (1) HUE046858T2 (uk)
MX (2) MX350306B (uk)
NZ (3) NZ604412A (uk)
PH (1) PH12012502428B1 (uk)
PL (1) PL2579901T3 (uk)
PT (1) PT2579901T (uk)
UA (2) UA113496C2 (uk)
WO (1) WO2011156619A2 (uk)
ZA (1) ZA201209411B (uk)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
US8647642B2 (en) 2008-09-18 2014-02-11 Aviex Technologies, Llc Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment
DK2525817T3 (en) 2010-01-21 2017-10-02 Univ Arkansas Vaccine vectors and methods for enhancing immune responses
EA030929B1 (ru) 2013-02-14 2018-10-31 Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Арканзас КОМПОЗИЦИИ И СПОСОБЫ УСИЛЕНИЯ ИММУННЫХ ОТВЕТОВ НА Eimeria ИЛИ ОГРАНИЧЕНИЯ ИНФЕКЦИИ Eimeria
HK1219045A1 (zh) * 2013-03-15 2017-03-24 The Board Of Trustees Of The University Of Arkansas 增强对肠道病原体免疫应答的组合物和方法
US20150044698A1 (en) * 2013-08-06 2015-02-12 Techlab, Inc. Outer membrane protein 18 as a diagnostic marker for campylobacter
JP2017523136A (ja) * 2014-06-05 2017-08-17 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー 抗体誘導ワクチン及び迅速な成熟免疫応答の発生のための使用方法
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN105223362B (zh) * 2015-09-10 2016-08-31 上海慧耘生物科技有限公司 空肠弯曲菌酶联免疫检测试剂盒
BR112018072592A2 (pt) 2016-05-03 2019-04-16 The Board Of Trustees Of The University Of Arkansas vetor de vacina de levedura que inclui polipeptídeos imunoestimulantes e antigênicos, e métodos de uso dos mesmos
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3415145B2 (ja) 1991-03-05 2003-06-09 ザ ウエルカム ファウンデーション リミテッド 弱毒化細菌における組換えタンパク質の発現
US7405270B2 (en) 1991-10-25 2008-07-29 Immunex Corporation CD40-Ligand lacking native-pattern glycosylation
US5962406A (en) 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5981724A (en) 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
KR100283541B1 (ko) 1991-10-25 2001-03-02 크리스토퍼 엘. 와이트, 스코트 지. 홀퀴스트, 스티븐 엘. 말라스카 신규 사이토킨
EP0659086B1 (en) 1992-09-04 1998-11-11 The University of Saskatchewan Novel bacterial vaccines using vaccine strains of pathogenic bacteria
AU1059095A (en) 1993-11-24 1995-06-13 Australian National University, The Treatment of viral disease with cd40l peptide
EP0812206B1 (en) 1995-03-01 2002-07-10 Immunex Corporation Cd40 binding protein for stimulating an immune response
ES2214541T3 (es) 1995-06-07 2004-09-16 Immunex Corporation Muteina de cd40l.
US6713279B1 (en) 1995-12-07 2004-03-30 Diversa Corporation Non-stochastic generation of genetic vaccines and enzymes
US6479258B1 (en) 1995-12-07 2002-11-12 Diversa Corporation Non-stochastic generation of genetic vaccines
US6306387B1 (en) 1997-05-29 2001-10-23 The Research Foundation Of State University Of New York Antigen delivery system
US6969609B1 (en) 1998-12-09 2005-11-29 The United States Of America As Represented By The Department Of Health And Human Serivces Recombinant vector expressing multiple costimulatory molecules and uses thereof
CA2223225A1 (en) 1997-11-28 1999-05-28 Canadian Red Cross Society Method for inhibiting in vivo immune response
AU2004199A (en) 1997-12-19 1999-07-12 Immunex Corporation Method for reducing susceptibility to hiv infection
GB9806449D0 (en) 1998-03-25 1998-05-27 Peptide Therapeutics Ltd Attenuated bacteria useful in vaccines
US6190669B1 (en) 1998-05-13 2001-02-20 University Of Maryland, Baltimore Attenuated mutants of salmonella which constitutively express the Vi antigen
IT1299583B1 (it) 1998-05-19 2000-03-16 Vander Way Limited Uso di proteine hmg-i per la preparazione di medicamenti ad attivita' citotossica
DK1108034T3 (da) 1998-09-04 2008-11-10 Emergent Product Dev Uk Ltd Svækkede salmonella SPI2-mutanter som antigenbærere
US7300774B1 (en) 1999-12-09 2007-11-27 The Regents Of The University Of California Multimeric fusion proteins of the TNF superfamily ligands
JP2000351735A (ja) * 1999-04-09 2000-12-19 Akzo Nobel Nv カンピロバクターワクチン
AU3966200A (en) 1999-04-16 2000-11-02 F. Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
EP1067194A1 (en) 1999-04-16 2001-01-10 F. Hoffmann-La Roche Ag Vectors containing a gene coding for CD40 and/or CD40L under the control of a cytokine-inducible promoter which is a human acute phase amyloid A gene promoter. Methods for their production and uses thereof
AU1084901A (en) 1999-10-14 2001-04-23 Martha S. Hayden-Ledbetter Dna vaccines encoding antigen linked to a domain that binds cd40
ES2222152T3 (es) 1999-12-28 2005-02-01 Akzo Nobel N.V. Vacuna con las salmonellas que no inducen anticuerpos que reaccionan con la flagelina o los flagelos.
US7371392B2 (en) 2000-02-02 2008-05-13 The United States Of America As Represented By The Department Of Health And Human Services Cd40 ligand adjuvant for respiratory syncytial virus
DE60112413T2 (de) 2000-03-17 2006-06-01 Pharmacia & Upjohn Co. Llc, Kalamazoo Ssa inaktivierte salmonella impfstoffe
GB0015426D0 (en) 2000-06-24 2000-08-16 Univ Southampton Method for generating soluble highly multimeric proteins
US20030165538A1 (en) 2000-06-26 2003-09-04 Maxygen Incorporated Methods and compositions for developing spore display systems for medicinal and industrial applications
WO2002036769A2 (en) 2000-10-31 2002-05-10 F. Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
US7220723B2 (en) 2001-05-15 2007-05-22 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
CZ20033402A3 (cs) 2001-05-15 2004-10-13 Northáshore@Longáislandájewisháresearcháinstitute Použití fragmentů HMG jako protizánětlivých činidel
CA2447593C (en) 2001-05-15 2014-07-08 Ortho-Mcneil Pharmaceutical, Inc. Ex-vivo priming for generating cytotoxic t lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease
ITMI20011986A1 (it) 2001-09-25 2003-03-25 San Raffaele Centro Fond Metodo e composizione per l'attivazione di cellule presentanti l'antigene
DE50212280D1 (de) 2001-12-19 2008-06-26 Alcedo Biotech Gmbh Verwendung von hmgb-proteinen und dafür codierenden nukleinsäuren
US6923958B2 (en) 2002-03-02 2005-08-02 The Scripps Research Institute DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof
EP1499191B1 (en) 2002-04-15 2012-05-09 Washington University in St. Louis Regulated attenuation of live vaccines to enhance cross protective immunogenicity
US7495090B2 (en) 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
WO2004046345A2 (en) 2002-11-20 2004-06-03 Critical Therapeutics, Inc. Use of hmgb fragments as anti-inflammatory agents
US20040156851A1 (en) 2002-11-20 2004-08-12 Critical Therapeutics, Inc. HMGB1 combination therapies
US20040141948A1 (en) 2002-11-20 2004-07-22 Critical Therapeutics, Inc. Use of HMGB fragments as anti-inflammatory agents
WO2004046338A2 (en) 2002-11-20 2004-06-03 North Shore-Long Island Jewish Research Institute Use of hmgb polypeptides for increasing immune responses
US20050181994A1 (en) 2003-01-06 2005-08-18 Xencor, Inc. Novel variants of CD40L protein
US20060014248A1 (en) 2003-01-06 2006-01-19 Xencor, Inc. TNF super family members with altered immunogenicity
US7696169B2 (en) 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
WO2005025604A2 (en) 2003-09-10 2005-03-24 The General Hospital Corporation Use of hmgb and hmgb fragments to decrease specific immune response
WO2005035570A2 (en) 2003-10-10 2005-04-21 Xencor, Inc. Variants of cd40l protein
PL1694697T3 (pl) 2003-11-21 2011-05-31 Ace Biosciences As Zlokalizowane na powierzchni polipeptydy campylobacter jejuni
US8828957B2 (en) 2003-12-11 2014-09-09 Microvax, Llc Methods for generating immunity to antigen
EP1720905A2 (en) 2003-12-11 2006-11-15 Sidney Kimmel Cancer Center Methods for generating immunity to antigen
JP2008508855A (ja) * 2004-04-27 2008-03-27 インターツェル・アクチェンゲゼルシャフト Ｔｄ抗原
WO2005113598A2 (en) 2004-05-21 2005-12-01 Xencor, Inc. Tnf super family members with altered immunogenicity
US20080305120A1 (en) 2004-06-17 2008-12-11 Medimmune, Inc. Immunogenic Compositions Comprising Hmgb 1 Polypeptides
US20080075728A1 (en) 2004-07-20 2008-03-27 Walter Newman Combination Therapies Of Hmgb And Complement Inhibitors Against Inflammation
EP1809737B9 (en) 2004-10-07 2011-10-05 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
US8513008B2 (en) 2004-10-07 2013-08-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
GB0423681D0 (en) * 2004-10-26 2004-11-24 Sec Dep For Environment Food & Vaccine and nucleic acids
WO2006105972A1 (en) 2005-04-07 2006-10-12 Universite Libre De Bruxelles Transgenic organism expressing cd40l and uses thereof
US20060286074A1 (en) 2005-05-31 2006-12-21 Yucheng Tang Methods for immunotherapy of cancer
WO2007011606A2 (en) 2005-07-18 2007-01-25 Critical Therapeutics, Inc. USE OF HMGBl ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS
BRPI0616978A2 (pt) 2005-10-07 2011-07-05 Proyecto Biomedicina Cima Sl combinação imuno-estimulante para a profilaxia e tratamento de hepatite c, sua utilização, composição farmacêutica que a contém, kit para sua administração, método para produzir uma resposta imune e vacina contra o vìrus da hepatite c
AU2006311752A1 (en) 2005-11-07 2007-05-18 Sidney Kimmel Cancer Center CD40 ligand fusion protein vaccine
WO2007054658A1 (en) 2005-11-14 2007-05-18 King's College London Control of immune responses
WO2007130725A2 (en) 2006-02-06 2007-11-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of hmgb1 for protection against ischemia reperfusion injury
WO2007103048A2 (en) 2006-03-01 2007-09-13 Regents Of The University Of Colorado Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
WO2007106073A2 (en) * 2006-03-02 2007-09-20 University Of Massachusetts Modified pathogens for use as vaccines
EP2043434A4 (en) 2006-07-10 2010-01-27 Univ Arizona State CAMPYLOBACTER PILUS PROTEIN, COMPOSITIONS AND METHOD
JP2010500034A (ja) 2006-08-09 2010-01-07 メッドイミューン バクシーンズ，インコーポレイティド インフルエンザ赤血球凝集素変異体およびノイラミニダーゼ変異体
KR101460551B1 (ko) 2006-09-18 2014-11-18 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 면역 반응을 향상시키는 조성물 및 방법
EP2139913A4 (en) 2007-03-08 2011-09-21 Mayo Foundation INTRODUCTION OF IMMUNE-MEDIUM TUMOR CELL DEOD
AU2008318615A1 (en) 2007-10-30 2009-05-07 Texas A&M University System Compositions and methods of enhancing immune responses to flagellated bacterium
CA2704422C (en) 2007-11-01 2019-09-24 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to eimeria
CN101332304A (zh) * 2008-08-05 2008-12-31 扬州大学 一种空肠弯曲菌壳聚糖纳米dna疫苗及其制备方法和应用
DK2525817T3 (en) * 2010-01-21 2017-10-02 Univ Arkansas Vaccine vectors and methods for enhancing immune responses

Also Published As

Publication number Publication date
US20150190496A1 (en) 2015-07-09
US8961990B2 (en) 2015-02-24
PL2579901T3 (pl) 2020-02-28
WO2011156619A2 (en) 2011-12-15
AU2017202104A1 (en) 2017-04-20
ES2753142T3 (es) 2020-04-07
US10960068B2 (en) 2021-03-30
NZ702839A (en) 2016-04-29
KR20180085064A (ko) 2018-07-25
EP2579901A2 (en) 2013-04-17
EP2579901A4 (en) 2013-11-06
MX377650B (es) 2025-03-11
US20130084304A1 (en) 2013-04-04
DK2579901T3 (da) 2019-11-04
NZ604412A (en) 2015-01-30
PH12012502428B1 (en) 2019-01-23
HUE046858T2 (hu) 2020-03-30
AU2015243062B2 (en) 2017-05-04
AU2011264772A1 (en) 2013-01-24
KR20130088122A (ko) 2013-08-07
BR112012031211A2 (pt) 2018-01-30
EP3556397A1 (en) 2019-10-23
KR101881611B1 (ko) 2018-07-25
AU2011264772B2 (en) 2015-07-16
CN102971008A (zh) 2013-03-13
EA201291373A1 (ru) 2013-05-30
PT2579901T (pt) 2019-11-05
MX350306B (es) 2017-09-04
AR081856A1 (es) 2012-10-24
MX2012014395A (es) 2013-02-26
EP2579901B1 (en) 2019-08-07
KR102008120B1 (ko) 2019-08-07
ZA201209411B (en) 2015-05-27
AU2015243062A1 (en) 2015-11-12
CO6670521A2 (es) 2013-05-15
KR20180126618A (ko) 2018-11-27
UA113496C2 (xx) 2017-02-10
KR102007132B1 (ko) 2019-08-05
NZ718006A (en) 2017-06-30
JP2013537401A (ja) 2013-10-03
CN102971008B (zh) 2015-11-25
AU2011264772A2 (en) 2013-02-14
CL2012003458A1 (es) 2013-04-05
CA2800830A1 (en) 2011-12-15
CA2800830C (en) 2020-09-08
JP5746333B2 (ja) 2015-07-08
PH12012502428A1 (en) 2013-02-18
EA030793B1 (ru) 2018-09-28
AU2017202104B2 (en) 2018-08-23
WO2011156619A3 (en) 2012-02-16

Similar Documents

Publication Publication Date Title
UA116915C2 (uk) Вектор, що кодує антигенний пептид, та спосіб підвищення стійкості до інфекцій, що викликаються campylobacter
SG10201907522QA (en) Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
IN2014DN09351A (uk)
WO2015024668A3 (en) Respiratory syncytial virus (rsv) vaccine
EA202090699A3 (ru) Композиции, содержащие буфер, вакцины, которые содержат композиции, содержащие буфер, и пути их применения
MX361728B (es) Ácido nucleico que comprende o codifica un tallo-bucle de histona y una secuencia poli(a) o una señal de poliadenilación para incrementar la expresión de un antígeno tumoral codificado.
MX391136B (es) FRAGMENTOS DE OspA ESTABILIZADOS CON CISTEÍNA Y MÉTODO DE USO
EA201890355A1 (ru) Новые способы индукции иммунного ответа
HK1225631A1 (zh) 免疫原性中东呼吸综合征冠状病毒(mers-cov)组合物和方法
EA201391183A1 (ru) Способы усиления иммуногенспецифических иммунных ответов при помощи векторных вакцин
MX346475B (es) Peptidos inmunogenicos monomericos y multimericos.
MX2017016401A (es) Composiciones inmunogenas.
EA201300132A1 (ru) Фармацевтическая композиция и методы лечения и профилактики заболеваний, вызванных вич или ассоциированных с вич
GB201118201D0 (en) Novel peptides
PH12015502844A1 (en) Mammalian milk osteopontin for enhancing immune responsiveness
NZ704188A (en) Attenuated swine influenza vaccines and methods of making and use thereof
UA114298C2 (uk) Пептид торк та вакцина, що його містить
MY167069A (en) Antigen peptide and use thereof
NZ700467A (en) Treatments suitable for malassezia infections
WO2013084070A3 (en) Salmonella vaccine proteins
EP4461365A3 (en) Respiratory syncytial virus (rsv) vaccine
BR112013007308A2 (pt) vacina
MX2011007602A (es) Composiciones de peptidos para el tratamiento y diagnostico de la fiebre por virus dengue.
UA106111C2 (uk) Спосіб отримання людського інтерферону з використанням наночастинок оксиду церію
UA99801C2 (uk) Білкова конструкція, яка включає модифікований поліпептид casb7439